DRAP 470 Compliance
Pharmaceutical Serialization & Track and Trace
Enhanced Security with Centralized Monitoring:
The Drug Regulatory Authority of Pakistan (DRAP) has introduced Rule 470 under the Drugs (Licensing, Registering & Advertising) Rules, 1976, mandating serialization and traceability for pharmaceutical products. DRAP 470 is designed to combat counterfeit medicines, ensure patient safety, and strengthen regulatory oversight across the pharmaceutical supply chain. For manufacturers, importers, distributors, and marketers, compliance is no longer optional—it is a critical requirement to operate in the regulated pharmaceutical market of Pakistan. Authentik provides a robust, centralized monitoring platform that enables pharmaceutical companies to achieve full DRAP 470 compliance. By implementing secure serialization, real-time tracking, and end-to-end visibility, Authentik ensures that every medicine pack can be uniquely identified, authenticated, and traced from production to dispensing.
The Drug Regulatory Authority of Pakistan (DRAP) has introduced Rule 470 under the Drugs (Licensing, Registering & Advertising) Rules, 1976, mandating serialization and traceability for pharmaceutical products. DRAP 470 is designed to combat counterfeit medicines, ensure patient safety, and strengthen regulatory oversight across the pharmaceutical supply chain. For manufacturers, importers, distributors, and marketers, compliance is no longer optional—it is a critical requirement to operate in the regulated pharmaceutical market of Pakistan. Authentik provides a robust, centralized monitoring platform that enables pharmaceutical companies to achieve full DRAP 470 compliance. By implementing secure serialization, real-time tracking, and end-to-end visibility, Authentik ensures that every medicine pack can be uniquely identified, authenticated, and traced from production to dispensing.
Safeguard Your Pharmaceutical Brand with Authentik
Authentik’s DRAP 470–ready Track & Trace solution assigns a unique serialized code to each saleable unit, bundle, case, and pallet, fully aligned with GS1 standards. These codes are securely generated, printed, verified, and stored within a centralized system approved for regulatory reporting.
Through Authentik, pharmaceutical brands can protect patients from counterfeit or substandard medicines, prevent unauthorized parallel trade, and maintain full control over product movement. The solution also supports seamless reporting to DRAP, reducing compliance risk and audit complexity.
Key Challenges Addressed Under DRAP 470
Counterfeit and Falsified Medicines
Illegitimate drugs pose serious health risks and undermine trust in healthcare systems. DRAP 470 aims to eliminate these threats through serialization and verification.Limited Supply Chain Visibility
Without traceability, tracking product movement across distributors, wholesalers, and retailers becomes extremely difficult.Regulatory Compliance Pressure
Manufacturers face strict timelines, data accuracy requirements, and penalties for non-compliance.Product Recalls and Pharmacovigilance
Lack of batch and unit-level traceability delays recalls and increases patient risk.Key Features of Authentik DRAP 470 Solution
- End-to-End Serialization: Unique identification of primary, secondary, and tertiary packaging levels.
- Real-Time Track & Trace: Complete visibility across manufacturing, distribution, and dispensing points.
- Regulatory Reporting & Compliance: Automated, accurate data reporting aligned with DRAP requirements.
- Secure Cloud-Based Architecture: Scalable, validated, and compliant with pharmaceutical data integrity standards.
- Recall & Expiry Management: Rapid identification and isolation of affected products to protect patients.
Advanced Anti-Counterfeiting Technology
Secure data matrix codes and authentication layers prevent duplication, tampering, and reuse.
Tailored for Pakistani Pharmaceutical Market
Designed specifically to meet DRAP regulations while supporting future global compliance needs.
Improved Stakeholder Trust
Enables pharmacists, regulators, and patients to verify medicine authenticity with confidence.
Conclusion:
DRAP 470 represents a major step toward a safer, more transparent pharmaceutical ecosystem in Pakistan. Compliance requires more than just serialization it demands a reliable, scalable, and regulator-ready track and trace infrastructure. Authentik empowers pharmaceutical companies to meet DRAP 470 requirements efficiently while strengthening brand protection, patient safety, and operational excellence. With Authentik, compliance becomes a strategic advantage rather than a regulatory burden.